In the rapidly evolving landscape of digital health, artificial intelligence (AI) is driving transformative change. A prime example is the BREATHE project, an initiative supported by EIT Health, which is developing evernoa—an AI-powered solution that leverages exhaled biomarkers to enhance the management of asthma and chronic obstructive pulmonary disease (COPD). With the potential to reduce exacerbations by up to 55%, this technology could significantly decrease hospitalizations and improve the lives of millions.
As part of its ongoing contribution to respiratory health, the BREATHE project will be featured at AstraZeneca’s panel discussion, "Respirando Futuro: Soluciones Innovadoras para la Prevención en Salud Respiratoria." This session will explore how AI-driven solutions are reshaping prevention strategies and improving patient outcomes. The event will highlight evernoa’s role in enabling early intervention through biomarker analysis, helping to reduce exacerbations and optimize treatment decisions.
According to Leyre Ruete Ibarrola, Co-founder and CEO of everSens,:
- “BREATHE represents our commitment to advancing respiratory health through AI. Thanks to EIT Health and our collaboration with leading research and technology partners, we are efficiently bringing innovative solutions to market, improving healthcare, and ensuring system sustainability.”
Dr. César Velasco, Director of Innovation and Digital Strategy at AstraZeneca Spain, reinforces this vision:
- “BREATHE exemplifies the power of collaboration in revolutionizing healthcare. Our involvement in this initiative aligns with our commitment to an integrated and patient-centered approach to respiratory diseases.”
Izabel Alfany, Managing Director of the EIT Health Spain Foundation adds:
- “Our commitment to this project, and to the stakeholders forming its consortium, reflects our strong dedication to leading a culture of innovation in Spain, while simultaneously advancing tangible improvements in healthcare and the quality of life for patients with chronic respiratory diseases such as asthma and COPD.”
Jordi Ortiz, Senior Consultant and Director of Quality at GENESIS Biomed, highlighted that:
- “The BREATHE project, funded by EIT Health, represents a crucial step for GENESIS Biomed, strengthening our commitment to innovative solutions in the healthcare sector. This initiative builds upon our ongoing support for everSens, further enhancing our expertise in respiratory health management and patient care.”
BREATHE at the 4YFN25 x MWC25 Ecosystem
The impact of evernoa and the BREATHE project extends beyond individual treatment, shaping the future of digital health. Events like 4YFN25 and MWC25 provide a unique platform where startups, investors, and industry leaders converge to explore cutting-edge health innovations.
By integrating AI into healthcare solutions, projects like BREATHE not only improve clinical outcomes but also create investment opportunities in scalable, high-impact technologies. Their presence at leading industry events fosters collaboration between startups, corporations, and research institutions, positioning Europe as a global leader in digital health innovation.
With its focus on AI, biomarker-based diagnostics, and interdisciplinary collaboration, BREATHE stands at the forefront of the digital health revolution. As the industry continues to evolve, initiatives like evernoa showcase how technology is redefining patient care while improving healthcare efficiency.
The transformation of digital health is already underway, and projects like BREATHE are leading the way. Major industry events such as 4YFN and MWC underscore the importance of global collaboration in accelerating next-generation healthcare solutions.
To know more about 4YFN Digital Health programme you can visit our website here.